Literature DB >> 557772

Ultrastructural localization of the acetylcholine receptor in myasthenia gravis and in its experimental autoimmune model.

A G Engel, J M Lindstrom, E H Lambert, V A Lennon.   

Abstract

Peroxidase-conjugated alpha-bungarotoxin (P-BGT) was used for the ultrastructural localization of the acetylcholine receptor in end-plates in external intercostal muscles of four patients with myasthenia gravis, in forelimb digit extensor muscles of rats with advanced chronic experimental autoimmune myasthenia gravis, and in suitable human and rat controls. In control end-plates, the previously reported localization of acetylcholine receptor on the terminal expansions of the postsynaptic folds and, in traces, on the presynaptic membrane was confirmed. By contrast, in myasthenia gravis some postsynaptic regions bound no P-BGT; in other regions, the folds displayed only faint traces of the reaction product, or only some segments of the postsynaptic membrane showed the reaction product; finally, in some regions there was no apparent decrease in reaction product. In general, those postsynaptic regions showing the greatest decrease in P-BGT binding were also the simplest or showed the most degenerative changes, and the presynaptic staining was decreased in proportion to the decrease in the adjacent postsynaptic P-BGT binding. In the experimental animals, the abnormalities in the amount and distribution of the acetylcholine receptor were essentially like those in the more severely affected patients. Morphometric estimates of the postsynaptic acetylcholine receptor surface correlated well with the patients' clinical status and linearly with the miniature end-plate potential amplitude.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 557772     DOI: 10.1212/wnl.27.4.307

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  59 in total

1.  Slow-channel myasthenic syndrome caused by enhanced activation, desensitization, and agonist binding affinity attributable to mutation in the M2 domain of the acetylcholine receptor alpha subunit.

Authors:  M Milone; H L Wang; K Ohno; T Fukudome; J N Pruitt; N Bren; S M Sine; A G Engel
Journal:  J Neurosci       Date:  1997-08-01       Impact factor: 6.167

Review 2.  Immunopathologic events at the endplate in myasthenia gravis.

Authors:  T Ashizawa; S H Appel
Journal:  Springer Semin Immunopathol       Date:  1985

3.  hnRNP H enhances skipping of a nonfunctional exon P3A in CHRNA1 and a mutation disrupting its binding causes congenital myasthenic syndrome.

Authors:  Akio Masuda; Xin-Ming Shen; Mikako Ito; Tohru Matsuura; Andrew G Engel; Kinji Ohno
Journal:  Hum Mol Genet       Date:  2008-09-20       Impact factor: 6.150

4.  DPAGT1 myasthenia and myopathy: genetic, phenotypic, and expression studies.

Authors:  Duygu Selcen; Xin-Ming Shen; Joan Brengman; Ying Li; Anthony A Stans; Eric Wieben; Andrew G Engel
Journal:  Neurology       Date:  2014-04-23       Impact factor: 9.910

5.  Myasthenia gravis: further electrophysiological and ultrastructural analysis of transmission failure in the mouse passive transfer model.

Authors:  K V Toyka; K L Birnberger; A P Anzil; C Schlegel; U Besinger; A Struppler
Journal:  J Neurol Neurosurg Psychiatry       Date:  1978-08       Impact factor: 10.154

6.  Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection.

Authors:  Feng Lin; Henry J Kaminski; Bianca M Conti-Fine; Wei Wang; Chelliah Richmonds; M Edward Medof
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

Review 7.  Myasthenia gravis--current concepts.

Authors:  C Herrmann; J M Lindstrom; J C Keesey; D G Mulder
Journal:  West J Med       Date:  1985-06

8.  Synthesizing enzymes for four neuroactive substances in motor neurons and neuromuscular junctions: light and electron microscopic immunocytochemistry.

Authors:  V Chan-Palay; A G Engel; S L Palay; J Y Wu
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

9.  Induction of the morphologic changes of both acute and chronic experimental myasthenia by monoclonal antibody directed against acetylcholine receptor.

Authors:  C M Gomez; R L Wollmann; D P Richman
Journal:  Acta Neuropathol       Date:  1984       Impact factor: 17.088

10.  Spectrotypic analysis of antibodies to acetylcholine receptors in experimental autoimmune myasthenia gravis.

Authors:  A Bionda; M H De Baets; S J Tzartos; J M Lindstrom; W O Weigle; A N Theophilopoulos
Journal:  Clin Exp Immunol       Date:  1984-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.